{"commentary":{"count":25,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":14,"podcast":10,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04002297\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MANGROVE","nct_id":"NCT04002297","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mangrove-nct04002297. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MANGROVE","arms":[{"description":"Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression.","label":"Arm A: zanubrutinib plus rituximab","type":"EXPERIMENTAL"},{"description":"Participants will receive bendamustine plus rituximab, followed by observation.","label":"Arm B: bendamustine plus rituximab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-09-30","type":"ESTIMATED"},"conditions":["Mantle Cell Lymphoma; Non-Hodgkin Lymphoma"],"enrollment":{"count":510,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"zanubrutinib","type":"DRUG"},{"name":"bendamustine","type":"DRUG"},{"name":"rituximab","type":"DRUG"}],"last_update":"2026-09-30","lead_sponsor":"BeOne Medicines","official_title":"A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-04-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) determined by independent central review","timeFrame":"Up to approximately 7 years"}],"references":[{"citation":"Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021 Jan;17(3):255-262. doi: 10.2217/fon-2020-0794. Epub 2020 Sep 28.","pmid":"32985902","type":"DERIVED"}],"start_date":{"date":"2019-08-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation","url":"https://clinicaltrials.gov/study/NCT04002297"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mangrove-nct04002297"}